Current Role of Ablation in Liver Cancer Therapy (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 65
Special Issue Editors
Interests: hepatocellular carcinoma; hepatobiliary tumors; hepatobiliary surgery; liver transplantation; prognostic/staging systems
Special Issues, Collections and Topics in MDPI journals
Interests: transplantation; liver transplantation; surgery; hepatobiliary surgery; laparoscopic surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Ablation therapy is a well-recognized option among hepatocellular carcinoma (HCC) treatments. Since its introduction, it has progressively gained approval and is now included in the European, American and Asiatic HCC management guidelines as a reliable approach. Moreover, there is increasing evidence that ablation therapy could also represent a potentially curative option for other types of liver cancer (i.e., cholangiocarcinoma, colorectal or breast cancer liver metastases). Despite these improvements, however, some innovations are still expected and desirable.
This Special Issue aims to explore the field of ablation in liver cancer therapy, examining innovative aspects and further developing the poorly defined ones. The scope encompasses additional evidence on the potential role of liver ablation for non-HCC liver cancers, such as cholangiocarcinoma, colorectal or breast cancer liver metastases. Furthermore, different ablation technologies, for example, microwave rather than radiofrequency, are available and worthy of comparison. Other technical aspects such as percutaneous or laparoscopic approaches could also be addressed for useful comparisons. Innovative combination techniques with trans-arterial chemoembolization or immunotherapy have also recently been developed and studied.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the extension of ablation indications to different types of liver cancers, technical and technological comparisons, as well as innovations in this field.
We look forward to receiving your contributions.
Prof. Dr. Alessandro Vitale
Prof. Dr. Umberto Cillo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ablation
- microwave
- radiofrequency
- percutaneous
- laparoscopic
- colorectal
- breast
- cancer
- combination
